Seeing the Future Through Science
This article discusses the scope and purpose of the special designation for Regenerative Medicine Advanced Therapies (RMAT) created by the passage of the 21st Century Cures […]
Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa (RP). Presented by David […]
In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute […]
May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for […]
Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy April 19, 2017 – Cell therapy company jCyte is launching a phase […]
The California Institute for Regenerative Medcine’s (CIRM’s) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the […]
Developing groundbreaking therapies can be maddeningly slow, but jCyte recently took a big step forward, receiving an $8.3 million grant from the California Institute for […]
Recently, the Gavin Herbert Eye Institute at UC Irvine profiled jCyte co-founder Jing Yang, MD, PhD, and retinitis pigmentosa trial participant Elaine Cain. The article highlights Dr. […]
November 28, 2016 – California-based regenerative medicine company jCyte has completed enrollment in a phase 1/2a trial to study the safety of its stem cell therapy candidate […]
Dr. Henry Klassen has spent decades working on a therapy for retinitis pigmentosa. In this recent Tedx presentation, Dr. Klassen recounts some of the ups […]